0A8E.LSE Xeris Biopharma Holdings, Inc.
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 0A8E.LSE undervalued?
Graham numberThe Graham number of Xeris Biopharma Holdings, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Xeris Biopharma Holdings, Inc. fundamental analysis
No fundamental analysis for Xeris Biopharma Holdings, Inc. yet.
Xeris Biopharma Holdings, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhib…
Full company profileXeris Biopharma Holdings, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Xeris Biopharma Holdings, Inc. annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.08M | 1.56M | 2.42M | 2.72M | 20.4M | 49.6M | 110M | 164M | 203M | 292M | 350M |
| Gross Profit | 951K | 1.38M | 2.10M | 41.0K | 11.2M | 35.9M | 76.8M | 135M | 155M | 238M | 293M |
| Operating Income | -13.2M | -26.6M | -59.3M | -122M | -81.8M | -105M | -80.5M | -44.0M | -33.6M | 24.9M | 26.2M |
| EBITDA | -13.1M | -26.5M | -59.0M | -121M | -82.4M | -114M | -69.3M | -30.9M | -11.3M | 37.6M | 39.0M |
| Net Income | -13.2M | -26.6M | -60.1M | -126M | -91.1M | -123M | -94.7M | -62.3M | -54.8M | 554K | -57.7M |
| EPS | -0.64 | -1.29 | -4.99 | -4.81 | -2.14 | -1.55 | -0.70 | -0.45 | -0.37 | 0.00 | -0.33 |
| Balance Sheet | |||||||||||
| Total Assets | 33.5M | 45.0M | 120M | 109M | 159M | 305M | 345M | 323M | 329M | 384M | 412M |
| Total Liabilities | 2.57M | 4.95M | 44.6M | 94.6M | 125M | 209M | 299M | 329M | 359M | 370M | 422M |
| Shareholders' Equity | 31.0M | 40.0M | 75.4M | 14.4M | 33.8M | 95.2M | 45.2M | -6.78M | -29.6M | 13.7M | -9.73M |
| Cash & Short-term Investments | 32.3M | 42.0M | 113M | 75.5M | 134M | 102M | 122M | 72.5M | 71.6M | 111M | 122M |
| Total Debt | - | - | 31.9M | 58.3M | 87.0M | 88.1M | 198M | 229M | 271M | 258M | 289M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -16.1M | -24.7M | -56.3M | -104M | -80.6M | -95.5M | -103M | -47.0M | -37.0M | 28.6M | 36.3M |
| Capital Expenditure | 35.0K | 700K | 1.51M | 1.11M | 377K | 1.09M | 524K | 2.26M | 868K | 696K | 1.07M |
| Free Cash Flow | -16.1M | -25.4M | -57.8M | -105M | -80.9M | -96.6M | -103M | -49.3M | -37.8M | 27.9M | 35.2M |
| Ratios | |||||||||||
| ROE | -42.7% | -66.3% | -79.7% | -869.9% | -270.0% | -128.9% | -209.5% | - | - | 4.0% | - |
| ROA | -39.4% | -59.0% | -50.1% | -115.2% | -57.3% | -40.3% | -27.5% | -19.3% | -16.7% | 0.1% | -14.0% |
| Net Profit Margin | -1,228.7% | -1,706.6% | -2,479.6% | -4,613.5% | -446.0% | -247.5% | -85.9% | -38.0% | -27.0% | 0.2% | -16.5% |
| Debt to Equity | - | - | 0.42x | 4.04x | 2.58x | 0.92x | 4.38x | - | - | 18.85x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Xeris Biopharma Holdings, Inc. dividends
Xeris Biopharma Holdings, Inc. has not paid dividends in the last 9 fiscal years.
Who owns Xeris Biopharma Holdings, Inc.
- Insiders 3.03%
- Institutions 61.87%
- Public & others 35.10%
- Free float 176M
Xeris Biopharma Holdings, Inc. company profile
- Company name
- Xeris Biopharma Holdings, Inc.
- Ticker
- 0A8E.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 435
- Fiscal year end
- December
- Address
- 1375 West Fulton Street, Chicago, IL, United States, 60607
- Phone
- 844 445 5704
- Website
- xerispharma.com
About Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Xeris Biopharma Holdings, Inc. management
8- Mr. John P. ShannonChairman & CEO · born 1962
- Mr. Kevin McCullochPresident & COO · born 1964
- Mr. Steven M. PieperChief Financial Officer · born 1977
- Ms. Beth P. Hecht J.D.Chief Legal Officer & Corporate Secretary · born 1964
- Dr. Anh T. Nguyen M.B.A., M.D.Chief Medical Officer · born 1975
- Mr. Brian ConnerSVP of Quality and Chief Compliance & Risk Officer
- Ms. Kendal KorteSenior Vice President of Human Resources
- Joshua BennettVice President of Strategy & Business Development